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Summary
Background.— Residual dyslipidaemia in patients treated with statins needs to be addressed to
reduce the prevalence of cardiovascular disease in primary and secondary care.
Aims.— To estimate the prevalence of residual lipid abnormalities in statin-treated patients in
France.
Methods.— Plasma concentrations of low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol and triglycerides were recorded in patients classiﬁed by cardiovascular risk
according to guidelines from Agence franc¸aise de sécurité sanitaire des produits de santé.
Recruitment took place between September 2008 and February 2009, and involved patients
aged > 45 years who had been on statin therapy for ≥ 3 months.
Results.— Overall, 39.6% of the 4335 statin-treated patients had lipid values within desir-
able levels. Low-density lipoprotein cholesterol was not at goal more often (51.8%) in higher
risk patients than in all patients averaged (37.2%). Also, high-risk patients with low-density
lipoprotein cholesterol not at goal had additional lipid abnormalities (low high-density lipopro-
tein cholesterol and/or high triglycerides) more frequently (25.6%) than all patients averaged
(18.4%).
Conclusion.— We conclude that a signiﬁcant proportion of dyslipidaemic patients at high car-
diovascular risk in France are not achieving treatment goals after statin treatment. A signiﬁcant
Abbreviations: Afssaps, Agence franc¸aise de sécurité sanitaire des produits de santé; BP, blood pressure; CV, cardiovascular; DYSIS,
Dyslipidemia International Study; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride levels.
More attention to the management of these patients is needed to use public health resources
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bénéﬁcier de thérapeutiques complémentaires destinées à améliorer le LDL-cholestérol, le HDL-
cholestérol ou les triglycérides. Une attention particulière doit être réservée à ces patients aﬁn
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Background
Lowering the prevalence of modiﬁable risk factors such
as dyslipidaemia, smoking or sedentary lifestyle has con-
tributed to reducing cardiovascular-related mortality [1—3].
In urban France, cardiovascular disease is the most frequent
cause of death in women and the second most frequent in
the general population, only recently surpassed by cancer
[4,5].
It is estimated that reduction of plasma cholesterol alone
prevented 24% of cardiovascular disease-related deaths
between 1980 and 2000 in the United States [6]. Many other
studies have similarly shown the beneﬁts of lipid-lowering
treatments not only on mortality [1—3] but also on morbidity
[7]. High circulating low-density lipoprotein (LDL) choles-
terol levels are most successfully treated with statins [8].
Every 1mmol/L reduction in LDL cholesterol is linked to a
24% decrease in mortality [3,9].
Residual dyslipidaemia remains for a signiﬁcant number
of treated patients. Some patients do not reach the intended
therapeutic goals for LDL cholesterol [10,11]. Signiﬁcant risk
associated with other lipid parameters represents additional
normal levels to be achieved. Thus, another group of dyslipi-
daemic patients at risk despite treatment are those with low
levels of high-density lipoprotein (HDL) cholesterol and/or
high levels of triglycerides [12—14]. Low HDL cholesterol is
in itself an established independent risk factor [15—17] and
high triglycerides may be too, although this is controversial
[18—21]. Statins are known to mildly augment blood levels of
HDL cholesterol (4—8%) and to reduce triglycerides (10—35%
depending on baseline triglyceride levels) [8,22].
S
T
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The Dyslipidemia International Study (DYSIS) was an epi-
emiological study recently conducted in Europe and Canada
ith the objective of evaluating the prevalence of resid-
al lipid abnormalities in patients receiving statin therapy.
n the present report, we perform a separate analysis on
he DYSIS cohort from France. The aim was to estimate the
revalence of different types of dyslipidaemia according to
he guidelines of the Agence franc¸aise de sécurité sanitaire
es produits de santé (Afssaps).
ethods
tudy population
s part of DYSIS, subjects were enrolled at 740 sites in
rance. The sample included outpatients managed by a fam-
ly practitioner or referred to a specialist (endocrinologist or
ardiologist) for the treatment of dyslipidaemia.
Eligible subjects were individuals older than 45 years,
ho had been on statin therapy for 3 months or longer and
ad at least one fasting blood lipid proﬁle within the past
months available while receiving statin therapy. Patients
articipating in other clinical studies were excluded from
ur study. Each site was allowed to enrol up to 10 consecu-
ive patients.303
proportion of these patients might beneﬁt from alternative therapies targeted at improvingmore effectively.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— Les anomalies lipidiques résiduelles chez les patients traités par statines doivent
être reconnues aﬁn de diminuer la prévalence de la maladie cardiovasculaire.
Objectifs.— Cette étude a été menée aﬁn d’estimer la prévalence des anomalies lipidiques
résiduelles chez des patients traités par statines en France.
Méthodes.— Les concentrations plasmatiques du LDL-cholestérol, du HDL-cholestérol et des
triglycérides ont été analysées chez les patients selon la classiﬁcation du risque établie par
l’Afssaps. Le recrutement s’est déroulé de septembre 2008 à fevrier 2009, incluant des patients
agés de 45 ans ou plus et sous statines depuis plus de trois mois.
Résultats.— Au total, 39,6 % des 4335 patients traités par statines ont des valeurs biologiques
lipidiques dans les valeurs souhaitables. Le LDL-cholestérol n’était pas à l’objectif thérapeu-
tique plus souvent (51,8 %) chez les sujets à haut risque par rapport à l’ensemble de l’échantillon
(37,2 %). De plus, les sujets à haut risque qui n’étaient pas à l’objectif thérapeutique pour
le LDL-cholestérol avaient des anomalies lipidiques complémentaires (cholestérol HDL bas ou
triglycérides élevés) plus fréquemment (25,6 %) par rapport à l’ensemble des patients (18,4 %).
Conclusions.— Une part signiﬁcative des patients traités par statines en France et à haut risque
ne sont pas aux objectifs thérapeutiques recommandés. Certains de ces patients pourraienttudy design and data collection
his was a cross-sectional study designed to estimate the
revalence of different types of dyslipidaemia in statin-
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reated patients. The study protocol was approved by the
elevant local ethical review committees. Patients who vis-
ted physicians, irrespective of the reason, and fulﬁlled the
nclusion criteria were invited to participate. They were
nformed of both the aims of the study and its protocol.
ata were collected from a single clinical examination and
rom medical charts.
Information was recorded on patient demographic data
sex, age), type of medical practice and location. Other
linical variables collected were: history of premature car-
iovascular disease in ﬁrst-degree relatives, smoking history,
ypertension, ischaemic heart disease, diabetes mellitus,
erebrovascular disease, peripheral artery disease, height,
eight, waist circumference, level of physical activity,
lcohol consumption, fasting plasma glucose and HbA1c.
ollowing the deﬁnition of the International Diabetes Feder-
tion, metabolic syndrome was considered to be present if
person had central obesity (waist circumference ≥ 94 cm
or Europid men and ≥ 80 cm for Europid women, with eth-
icity speciﬁc values for other groups) plus any two of
he following: triglycerides ≥ 1.7mmol/L (150mg/dL) or
peciﬁc treatment for this lipid abnormality; HDL choles-
erol < 1.0mmol/L (40mg/dL) in men and < 1.29mmol/L
50mg/dL) in women or speciﬁc treatment for this lipid
bnormality; systolic blood pressure (BP) ≥ 130 or dias-
olic BP ≥ 85mmHg or treatment of previously diagnosed
ypertension; and fasting plasma glucose ≥ 5.6mmol/L
100mg/dL) or previously diagnosed type 2 diabetes.
For this evaluation of the French population, patients
ere distributed into ﬁve risk categories, following the cri-
eria set forth by the Afssaps [23]. Each category is deﬁned
y the sum of risk factors applicable to an individual: 0, 1, 2,
3 or high risk. High-risk patients were considered as those
ith either proven coronary disease, or with diabetes plus
wo other cardiovascular risk factors. Cerebrovascular and
eripheral arterial diseases, considered here as separate
isease entities, were present only in patients at high risk.
Information collected on statin therapy included the
ame and daily dose of the statin and any other lipid-
odifying therapies used at the time of the blood lipid tests.
Laboratory results from patients, who had been on statin
herapy for 3 or more months, were included in the anal-
ses. Plasma lipid tests included in this study were: total
holesterol, LDL cholesterol, HDL cholesterol and triglyc-
rides, all expressed in mmol/L and in mg/dL. The results
ere analysed in the light of speciﬁc targets for every risk
evel, as recommended by the French guidelines for preven-
ion of cardiovascular risk (see below). The percentages of
atients within the therapeutic normal levels (i.e., at goal)
or single and combined lipid measurements are presented
n Venn diagrams.
The recommendations from the Afssaps [23] to deﬁne
he LDL-cholesterol targets were: in the absence of other
isk factors, the target LDL cholesterol for an individual
s 5.7mmol/L (220mg/dL); for patients with 1, 2, or ≥ 3
isk factors, it is 4.9, 4.1 and 3.4mmol/L (190, 160 and
30mg/dL), respectively; and for high-risk patients, the
arget is 2.6mmol/L (100mg/dL). HDL cholesterol below
.0mmol/L (40mg/dL) is a risk factor for both men and
omen. By contrast HDL cholesterol values > 1.5mmol/L
60mg/dL) are considered protective and computed as
−1) in the risk calculation equation. As no recommended
t
u
t
(J. Ferrières et al.
hreshold for plasma triglyceride concentrations is given in
he Afssaps guidelines, the one recommended (1.7mmol/L
150mg/dL]) by the European Society of Cardiology [24] was
sed.
tatistical analysis
ample-size estimations for a binomial proportion of preva-
ence of dyslipidaemia between 20 and 60% indicated that a
urvey on 4000 individuals would allow prevalence estima-
ions with precisions of between 1 and 2.5%.
Continuous variables, including patient characteristics,
re reported using descriptive statistics (mean± standard
eviation [SD] or median with Q1—Q3 interquartile range,
s appropriate). Categorical variables are presented as per-
entage and absolute number. The percentages of patients
lassiﬁed in the ﬁve risk categories were used to stratify the
esults for LDL cholesterol, HDL cholesterol and triglycerides
y risk category. Post-hoc analyses compared subgroups of
ombined lipid abnormalities (i.e., LDL cholesterol not at
oal, low HDL cholesterol and/or high triglycerides) by risk
evel. Distributions of single and multiple combined lipid
bnormalities were obtained and the prevalence of each
ipid proﬁle was calculated.
All analyses were performed with the Statistical Analyz-
ng System, version 9.1 (SAS Institute Inc., Cary, NC, USA).
atients who did not have values for the appropriate lipid
arameters were not included in the lipid analyses.
esults
atient characteristics
total of 4335 patients were recruited between September
008 and February 2009, 69.5% of whom came from pri-
ary care centres. Mean age was 64.7 years and 65.3% were
en. According to the risk-category classiﬁcation of the Afs-
aps, 61.6% of the participants were considered at high risk,
hereas only 5.9% had no additional risk factor (Table 1).
he most frequent clinical feature was hypertension (69.5%
f patients), with a mean systolic and diastolic BP in this
ohort of 134.0± 12.4 and 77.9± 8.3mmHg, respectively.
etabolic syndrome was seen in 59.6% of the patients,
oronary heart disease in 34.0%, diabetes in 32.9%, fam-
ly history of premature cardiovascular disease in 26.9%
nd obesity in 26.8%. The mean waist circumference of
he group was 98.9± 13.4 cm and the body mass index was
7.9± 4.8 kg/m2. Clinical characteristics and their distribu-
ion across risk groups are given in Table 1.
reatment
ost patients were on atorvastatin treatment (32.4%), sim-
astatin (26.7%), rosuvastatin (19.0%) or pravastatin (17.5%;
able 2). All the other lipid-modifying treatments were used
n combination with a statin. Among these, ezetimibe was
he most common, in 12.1% of patients; and ﬁbrates, nico-
inic acid and bile-acid sequestrants were less commonly
sed.
The statin dose potency used by most (74.2%) of
he patients was equivalent to simvastatin 20—40mg/day
Fig. 1).
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Table 1 Patient characteristics according to risk category.
Variable All patients Patients with risk factors or at high risk
0 RF 1 RF 2 RF ≥ 3 RF High risk
N (%) 4335 257 (5.9) 552 (12.7) 551 (12.7) 186 (4.3) 2669 (61.6)
Agea (years) 64.7 (10.1) 57.2 (9.3) 62.4 (10) 62.6 (9.0) 60.6 (8.1) 66.9 (9.8)
SBPa (mmHg) 134.0 (12.4) 129.8 (9.4) 132.9 (11.0) 134.3 (11.2) 136.0 (9.8) 134.4 (13.3)
DBPa (mmHg) 77.9 (8.3) 77.0 (6.8) 77.7 (7.7) 78.4 (7.9) 80.9 (7.6) 77.8 (8.6)
Waist circumferencea (cm) 98.9 (13.4) 92.0 (12.5) 95.2 (13.5) 97.6 (12.3) 100.7 (13.3) 100.6 (13.3)
BMIa 27.9 (4.8) 25.6 (4.1) 26.8 (4.6) 27.7 (5.0) 28.4 (4.1) 28.4 (4.8)
BMI ≥ 30 kg/m2 b (%) 26.8 11.3 19.8 22.7 33.5 30.5
Womenb (%) 34.7 61.1 52.4 40.8 31.2 27.4
Family history of premature
CV diseaseb,c (%)
26.9 5.4 13.2 24.7 66.7 29.9
Current smokerb (%) 11.6 2.3 4.5 9.4 29.0 13.3
Hypertensionb (%) 69.5 8.9 49.3 72.2 89.2 78.6
Ischaemic heart diseaseb (%) 34.0 0 0 0 0 55.1
Diabetes mellitusb (%) 32.9 1.9 10.9 11.4 0 48.2
Cerebrovascular diseaseb (%) 7.5 0 0 0 0 12.2
Peripheral artery diseaseb (%) 13.4 0 0 0 0 21.7
Metabolic syndromeb (%) 59.6 25.3 42.8 54.1 68.4 66.7
BMI: body mass index; DBP: diastolic blood pressure; RF: risk factor; SBP: systolic blood pressure.
a Mean± SD.
b Percentages calculated from total number of patients in each risk group.
den
n
51.8% of the patients had LDL-cholesterol concentrations
above those recommended.
The distribution of patients with low HDL cholesterol fol-
lowed a similar trend, with proportions increasing in the
higher risk groups. In the high-risk group, 22.8% of thec At least one ﬁrst-degree relative with myocardial infarction/sud
Lipid proﬁles by risk category
Mean average plasma concentrations of total cholesterol,
LDL cholesterol, HDL cholesterol and triglycerides are given
in Table 3. In absolute terms, little difference in lipid param-
eters was seen across the various risk categories. However,
the therapeutic targets for LDL cholesterol vary with the
number of risk factors, as detailed in the previous sec-
tion [23]. When the LDL-cholesterol results were examined,
taking into consideration the Afssaps target values, most
patients with 0 or 1 risk factor had their LDL cholesterol at
the recommended level (Table 4). The proportion of patients
with elevated LDL cholesterol increased steadily with the
Table 2 Lipid-modifying therapies.
Therapy All patients
(n = 4335)
Statin treatment (%)
Simvastatin 26.7
Atorvastatin 32.4
Rosuvastatin 19.0
Pravastatin 17.5
Fluvastatin 4.1
Unknown statin 0.3
Other lipid-modifying treatment (%) 13.3
Ezetimibe 12.1
Fibrate 0.7
Nicotinic acid 0.5
Bile-acid sequestrant 0.7 F
edeath before age 55 (men) or 65 (women).
umber of additional risk factors. In the high-risk group,igure 1. Statin use by dose potency in French patients. Potency
quivalence for different statins is shown in the table.
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Figure 2. Distribution of French patients according to lipid sta-
tus. * LDL cholesterol not at goal: ≥ 5.7/4.9/4.1/3.4/2.6mmol/L
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d220/190/160/130/100mg/dL, respectively). † Low HDL choles-
erol: ≤ 1.0mmol/L (40mg/dL). ‡ High triglycerides: ≥ 1.7mmol/L
150mg/dL).
atients had low HDL cholesterol (Table 4). In comparison
ith low HDL cholesterol, larger proportions of patients
ad triglycerides in excess of 1.7mmol/L (150mg/dL): from
8.7% of patients with 0 risk factors to 37.3% of the patients
n the high-risk group.
Combined lipid abnormalities were stratiﬁed by risk
roup (Table 4). The percentages of patients with LDL
holesterol not at goal plus low HDL cholesterol and/or high
riglycerides increased from 0.8% in the group with 0 risk
actors to 25.6% in patients at high risk.
revalence of abnormal lipid proﬁles
hen all of the patients were considered together, 62.8%
ad LDL cholesterol at goal, 39.6% had normal levels for
ll the lipid parameters and 23.2% had low HDL cholesterol
nd/or high triglycerides and LDL cholesterol at goal (Fig. 2).
lobally, 37.2% of patients had LDL cholesterol not at goal,
nd 18.4% had low HDL cholesterol and/or high triglycerides
nd LDL cholesterol not at goal.
Proportions of patients with all of the individual and
he combined lipid abnormalities are represented in Fig. 3.
n 4.7% of the overall patients all three parameters were
bnormal (Fig. 3 a). Among high-risk patients, 48.2% had
DL cholesterol at goal; 26.8% had all lipid parameters nor-
alized and 21.3% had at least one other lipid parameter
bnormal (Fig. 3b). Among all high-risk patients not attain-
ng the LDL cholesterol goal, 25.6% had at least another lipid
bnormality, and in 6.7% all three lipid parameters were
bnormal.iscussion
YSIS set out to estimate the prevalence of residual dyslipi-
aemia in statin-treated patients across Europe and Canada
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Table 4 Prevalence of patients whose lipid proﬁles were not at goal or were abnormal, by risk category.
All patients Patients with risk factors or at high risk
0 RF 1 RF 2 RF ≥ 3 RF High risk
Lipid status n = 4335 n = 257 n = 552 n = 551 n = 186 n = 2669
LDL cholesterol not at goal (%)
(≥ 5.7/4.9/4.1/3.4/2.6mmol/L)
(≥ 220/190/160/130/100mg/dL)
37.2 1.6 6.2 15.3 42.0 51.8
Low HDL cholesterol (%)
(≤ 1.0mmol/L; ≤ 40mg/L)
17.6 0.0 1.8 9.5 41.4 22.8
High triglycerides (%)
(≥ 1.7mmol/L; ≥ 150mg/dL)
33.9 18.7 22.8 33.5 41.4 37.3
LDL cholesterol not at goal plus low
HDL cholesterol and/or high
triglycerides (%)
18.4 0.8 1.9 6.7 27.8 25.6
isk fa
l
p
l
hHDL: high-density lipoprotein; LDL: low-density lipoprotein; RF: r
in the light of revised and uniﬁed criteria, and the lipid rec-
ommendations of the European Society of Cardiology [24].
The results of the study are expected to provide additional
information for future guidelines for the management of
dyslipidaemia, in particular for patients at high cardiovas-
cular risk. However, risk variables are not homogeneously
distributed throughout countries, and algorithms to strat-
ify cardiovascular risk have not been universally validated.
France, for example, has consistently been shown to have a
w
t
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Figure 3. Distribution of single and multiple combined lipid abnormal
high-risk patients.ctor.
ower prevalence of cardiovascular disease than most Euro-
ean countries [25], attributed in part to dietary habits and
ifestyle [26,27]. Variations exist in the pharmacokinetics,
alf-lives and active metabolites of the different statins, as
ell as in their effects on plasma lipids [8,28]. In spite of
his, the statin potency, normalized to that of simvastatin
28,29], was estimated to be in a narrow range, and the
reatment intensity across the 4335 patients can be consid-
red rather homogeneous.
ities in French patients with total lipid proﬁle: (a) all patients; (b)
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Together with possible differences in genetic predis-
osition [30], the aforementioned characteristics of the
rench cohort might signiﬁcantly change the cardiovascu-
ar risk map with respect to the overall DYSIS population.
t seems therefore sensible to analyse the lipid proﬁle of
he French population separately, according to its regional
eculiarities, to obtain a more realistic depiction of the
ipid status of each risk group. The representativity of the
rench DYSIS sample is questionable. However, the distribu-
ion of statin use in 2008 in the French representative Étude
ermanente de la prescription médicale (EPPM) survey
unpublished observations) was quite similar (atorvastatin
2%, pravastatin 22.5%, rosuvastatin 20.7%, simvastatin 19%,
uvastatin, 7%) to that observed in the DYSIS study.
The stratiﬁcation into ﬁve risk categories, based on the
ddition of risk factors in the Afssaps guidelines, delineates
more gradual distribution of risk than the one used in other
uidelines (i.e., low, high). Lipid abnormalities could there-
ore be allocated with greater precision to individuals at
ifferent levels of cardiovascular risk. As expected, patients
n low-risk groups were more frequently at goal than the
nes at high risk. Roughly half of the high-risk patients were
t the recommended levels for LDL cholesterol. This ﬁgure
s very close to the 44.8% recorded in the CEPHEUS study
erformed at the end of 2006 in France [11]. This highlights
hat despite the population and risk stratiﬁcation peculiar
o this study, secondary cardiovascular prevention in France
ould be improved substantially. Reducing further the popu-
ation at risk either by improving compliance or intensifying
reatment could help to achieve lower LDL-cholesterol lev-
ls in those patients who need them most. It was also
emarkable that about one in four patients at high risk also
ad low HDL cholesterol and high triglyceride concentra-
ions. This prevalence is in agreement with percentages of
1.2—26.9% observed in a European survey of 8545 dyslip-
daemic patients [15]. Statin therapy is unlikely to correct
uch abnormalities as it has only mild effects on these lipid
arameters [8]. Such patients would potentially beneﬁt from
lternative lipid-modifying therapies such as nicotinic acid
which has an effect on the three main lipid parameters)
r ﬁbrates (which have an effect mostly on triglycerides).
n additional group of patients, those with ≥ 3 risk factors,
ot strictly considered ‘high-risk’, would also beneﬁt from
reatment to increase low HDL cholesterol and reduce their
riglyceride concentrations. This group comprises a special
ype of patient, however, who can be considered ‘border-
ine’ between low and high risk.
Whether moderately high triglyceride levels are an inde-
endent cardiovascular risk factor is difﬁcult to ascertain
nd the Afssaps does not provide speciﬁc recommendations
n this respect. Although claims in support of this have
een made [18—20], no interventional study has been able
o associate lowering speciﬁcally triglyceride levels with
eductions of cardiovascular morbidity. Triglycerides also
resent pronounced intra-individual variation and high lev-
ls often accompany low HDL cholesterol, so that they may
epresent just an alternative index of a common metabolic
isturbance [21]. Notwithstanding this, we used the Euro-
ean Society of Cardiology cut-off value of 1.7mmol/L
150mg/dL), which is consistent with the reference values
n our population, but we did not regard it as an independent
isk factor in our study.J. Ferrières et al.
onclusions
early 40% of statin-treated patients in France could still
eneﬁt from LDL cholesterol reduction. Among patients
t high cardiovascular risk, half of them had higher LDL
holesterol levels than recommended and an additional
uarter had low HDL cholesterol and high triglyceride lev-
ls. One in four high-risk patients had LDL cholesterol not
t goal combined with additional lipid abnormalities. More
omprehensive lipid management strategies in this popu-
ation may decrease the prevalence of lipid abnormalities
nd contribute to further decreases in cardiovascular risk.
mprovements in the lipid management of high-risk patients
hould be a priority to help reduce the burden on public
ealth resources.
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